Tag Archives: Emerging Companies

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Video: Emerging Company CEOs Praise JOBS Act

medical_research

Passed in 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. In this short video, leading BIO Board Members and biotech company CEOs share the reasons why they feel the JOBS Act is critically important for today’s biotech industry. The JOBS Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Strongly Supports R&D Tax Credit Legislation

cells115x76

The House Ways and Means Committee posted the following message on its home page showing the support of several organizations, including BIO, for the American Research & Competitiveness Act (H.R. 4438): “Today, the National Association of Manufacturers, Chamber of Commerce, R&D Credit Coalition, and Biotechnology Industry Organization – representing thousands of small and large U.S. businesses – issued their support for H.R. 4438, a bipartisan, permanent extension of the research and development (R&D) tax credit. In their call for a permanent R&D Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

33713_Viehbacher_100x100 copy

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Hill’s Congress Blog: Innovation in medicine isn’t optional – it’s imperative

TheHill

Earlier this week, The Hill’s Congress Blog posted an op-ed penned by Andrew von Eschenbach and Paul Howard entitled, “Innovation in medicine isn’t optional – it’s imperative” highlighting the importance of encouraging innovation and preserving incentives for drug development. The authors recommend increased cooperation and collaboration between industry, academia, and regulators, in addition to recognition by the federal government that ‘a vibrant life-sciences industry will generate higher national productivity, lower total health care costs, and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,